每日服用与每日两次服用硝苯地平控制妊娠期和产后血压的比较

IF 1.5 4区 医学 Q3 OBSTETRICS & GYNECOLOGY
Jessica A Peterson, Isabelle C Band, Kelly Wang, Angela Bianco
{"title":"每日服用与每日两次服用硝苯地平控制妊娠期和产后血压的比较","authors":"Jessica A Peterson, Isabelle C Band, Kelly Wang, Angela Bianco","doi":"10.1055/a-2486-8840","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong> The objective of this study was to compare 60 mg daily (QD) extended released (XR) nifedipine to 30 mg twice daily (BID) for blood pressure (BP) control antepartum and postpartum.</p><p><strong>Study design: </strong> This is a retrospective chart review conducted at the Mount Sinai Health System. Patients admitted from January 1, 2015, to April 30, 2021, diagnosed with a hypertensive disorder of pregnancy, who received nifedipine XR 30 mg BID or 60 mg QD for intrapartum or postpartum BP control were included. The primary outcome was the need for up-titration (i.e., the need for an increase in nifedipine dose or addition of another antihypertensive) after reaching one of the study doses (30 mg BID or 60 mg QD). Patients were excluded if they had preexisting renal disease or were already on oral antihypertensives. In a 1:1 ratio between single- and twice-daily dosing groups, the sample size needed to detect a 20% difference in up-titration rate to achieve 0.80 power is 97 patients per group, for a total of 194 patients. This is based on a Pearson chi-square test with a significance level of 0.05.</p><p><strong>Results: </strong> A total of 237 patients were included, 139 (59%) received 30 mg BID and 98 (41%) 60 mg QD. There was no statistically significant difference in the need for an increase in nifedipine dose or addition of another oral antihypertensive agent between those receiving 30 mg BID versus 60 mg QD (33.8 vs. 35.7%; adjusted odds ratio [aOR], 95% confidence interval [CI]: 0.90 [0.50-1.60]; <i>p</i> = 0.71). There was no difference in the need for emergency hypertensive treatment after reaching the study dose (<i>p</i> = 0.19) or readmission for BP control between groups (<i>p</i> > 0.99).</p><p><strong>Conclusion: </strong> These findings suggest that BID dosing does not confer better BP control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance.</p><p><strong>Key points: </strong>· Nifedipine metabolism may increase in pregnancy.. · nifedipine 30 mg BID versus 60 mg QD were compared.. · There was no difference in the need for additional medication.. · There was no difference in the need for readmission.. · Daily dosing may be preferable for convenience..</p>","PeriodicalId":7584,"journal":{"name":"American journal of perinatology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum.\",\"authors\":\"Jessica A Peterson, Isabelle C Band, Kelly Wang, Angela Bianco\",\"doi\":\"10.1055/a-2486-8840\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong> The objective of this study was to compare 60 mg daily (QD) extended released (XR) nifedipine to 30 mg twice daily (BID) for blood pressure (BP) control antepartum and postpartum.</p><p><strong>Study design: </strong> This is a retrospective chart review conducted at the Mount Sinai Health System. Patients admitted from January 1, 2015, to April 30, 2021, diagnosed with a hypertensive disorder of pregnancy, who received nifedipine XR 30 mg BID or 60 mg QD for intrapartum or postpartum BP control were included. The primary outcome was the need for up-titration (i.e., the need for an increase in nifedipine dose or addition of another antihypertensive) after reaching one of the study doses (30 mg BID or 60 mg QD). Patients were excluded if they had preexisting renal disease or were already on oral antihypertensives. In a 1:1 ratio between single- and twice-daily dosing groups, the sample size needed to detect a 20% difference in up-titration rate to achieve 0.80 power is 97 patients per group, for a total of 194 patients. This is based on a Pearson chi-square test with a significance level of 0.05.</p><p><strong>Results: </strong> A total of 237 patients were included, 139 (59%) received 30 mg BID and 98 (41%) 60 mg QD. There was no statistically significant difference in the need for an increase in nifedipine dose or addition of another oral antihypertensive agent between those receiving 30 mg BID versus 60 mg QD (33.8 vs. 35.7%; adjusted odds ratio [aOR], 95% confidence interval [CI]: 0.90 [0.50-1.60]; <i>p</i> = 0.71). There was no difference in the need for emergency hypertensive treatment after reaching the study dose (<i>p</i> = 0.19) or readmission for BP control between groups (<i>p</i> > 0.99).</p><p><strong>Conclusion: </strong> These findings suggest that BID dosing does not confer better BP control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance.</p><p><strong>Key points: </strong>· Nifedipine metabolism may increase in pregnancy.. · nifedipine 30 mg BID versus 60 mg QD were compared.. · There was no difference in the need for additional medication.. · There was no difference in the need for readmission.. · Daily dosing may be preferable for convenience..</p>\",\"PeriodicalId\":7584,\"journal\":{\"name\":\"American journal of perinatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of perinatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2486-8840\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2486-8840","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究目的本研究旨在比较每日 60 毫克(QD)的硝苯地平缓释片(XR)与每日两次(BID)的 30 毫克硝苯地平缓释片在产前和产后控制血压方面的效果:这是一项在西奈山医疗系统进行的回顾性病历审查。纳入了 2015 年 1 月 1 日至 2021 年 4 月 30 日期间入院、确诊为妊娠期高血压疾病、接受硝苯地平 XR 30 毫克 BID 或 60 毫克 QD 用于产前或产后血压控制的患者。主要结果是达到研究剂量(30 毫克 BID 或 60 毫克 QD)之一后是否需要向上滴定(即是否需要增加硝苯地平剂量或添加另一种抗高血压药物)。患有肾脏疾病或正在口服抗高血压药物的患者将被排除在外。在单次给药组和每日两次给药组之间的比例为 1:1,为达到 0.80 的功率,检测出 20% 的升剂量差异所需的样本量为每组 97 名患者,共计 194 名患者。结果:共纳入 237 名患者,其中 139 人(59%)接受 30 毫克 BID 服药,98 人(41%)接受 60 毫克 QD 服药。接受 30 毫克 BID 和 60 毫克 QD 治疗的患者在需要增加硝苯地平剂量或增加另一种口服降压药方面没有统计学差异(33.8% vs 35.7%;aOR (95% CI):0.90 (0.50-1.60);p=0.71)。达到研究剂量后需要紧急高血压治疗(P=0.19)或因血压控制而再次入院的情况在各组之间没有差异(P>0.99):这些研究结果表明,在产前或产后,每日给药并不能更好地控制血压。因此,每日给药是合理的,可能更有利于患者的便利性和依从性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum.

Objective:  The objective of this study was to compare 60 mg daily (QD) extended released (XR) nifedipine to 30 mg twice daily (BID) for blood pressure (BP) control antepartum and postpartum.

Study design:  This is a retrospective chart review conducted at the Mount Sinai Health System. Patients admitted from January 1, 2015, to April 30, 2021, diagnosed with a hypertensive disorder of pregnancy, who received nifedipine XR 30 mg BID or 60 mg QD for intrapartum or postpartum BP control were included. The primary outcome was the need for up-titration (i.e., the need for an increase in nifedipine dose or addition of another antihypertensive) after reaching one of the study doses (30 mg BID or 60 mg QD). Patients were excluded if they had preexisting renal disease or were already on oral antihypertensives. In a 1:1 ratio between single- and twice-daily dosing groups, the sample size needed to detect a 20% difference in up-titration rate to achieve 0.80 power is 97 patients per group, for a total of 194 patients. This is based on a Pearson chi-square test with a significance level of 0.05.

Results:  A total of 237 patients were included, 139 (59%) received 30 mg BID and 98 (41%) 60 mg QD. There was no statistically significant difference in the need for an increase in nifedipine dose or addition of another oral antihypertensive agent between those receiving 30 mg BID versus 60 mg QD (33.8 vs. 35.7%; adjusted odds ratio [aOR], 95% confidence interval [CI]: 0.90 [0.50-1.60]; p = 0.71). There was no difference in the need for emergency hypertensive treatment after reaching the study dose (p = 0.19) or readmission for BP control between groups (p > 0.99).

Conclusion:  These findings suggest that BID dosing does not confer better BP control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance.

Key points: · Nifedipine metabolism may increase in pregnancy.. · nifedipine 30 mg BID versus 60 mg QD were compared.. · There was no difference in the need for additional medication.. · There was no difference in the need for readmission.. · Daily dosing may be preferable for convenience..

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of perinatology
American journal of perinatology 医学-妇产科学
CiteScore
5.90
自引率
0.00%
发文量
302
审稿时长
4-8 weeks
期刊介绍: The American Journal of Perinatology is an international, peer-reviewed, and indexed journal publishing 14 issues a year dealing with original research and topical reviews. It is the definitive forum for specialists in obstetrics, neonatology, perinatology, and maternal/fetal medicine, with emphasis on bridging the different fields. The focus is primarily on clinical and translational research, clinical and technical advances in diagnosis, monitoring, and treatment as well as evidence-based reviews. Topics of interest include epidemiology, diagnosis, prevention, and management of maternal, fetal, and neonatal diseases. Manuscripts on new technology, NICU set-ups, and nursing topics are published to provide a broad survey of important issues in this field. All articles undergo rigorous peer review, with web-based submission, expedited turn-around, and availability of electronic publication. The American Journal of Perinatology is accompanied by AJP Reports - an Open Access journal for case reports in neonatology and maternal/fetal medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信